Comparison of Repaglinide and Metformin Administered Alone or in Combination in Type 2 Diabetes

A 3-month, Open-label, Randomized, Multi-center Study of Repaglinide in Combination With Metformin as Compared to Metformin or Repaglinide Given as Monotherapy for the Treatment of Type 2 Diabetes.

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01720290

Enrollment

150

Registered

2012-11-02

Start date

2002-07-25

Completion date

2003-02-25

Last updated

2017-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Diabetes Mellitus, Type 2

Brief summary

This trial is conducted in Asia. The aim of this trial is to compare repaglinide and metformin administered alone or in combination in subjects with type 2 diabetes.

Interventions

DRUGrepaglinide

Dose individually adjusted

DRUGmetformin

Dose individually adjusted

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

35 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Previously treated with oral hypoglycaemic agents (OHA) as monotherapy (if metformin, less than 1500 mg daily) * Body Mass Index (BMI) of 21-35 kg/m\^2 * HbA1c (glycosylated haemoglobin A1c) between 7.0-10%

Exclusion criteria

* Treatment with insulin within the last 3 months preceding the trial * Uncontrolled treated or untreated hypertension (systolic blood pressure above or equal to 180 mm Hg, and/or diastolic blood pressure above 105 mm Hg) * Participation in any other clinical trial within 30 days of screening

Design outcomes

Primary

Measure	Time frame
Change in HbA1c (glycosylated haemoglobin A1c)	—

Secondary

Measure	Time frame
Fasting blood glucose (FBG)	—
1-hour post prandial blood glucose (PPBG)	—
Incidence of hypoglycemic episodes	—

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 9, 2026